Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | G6PC1 | P35575 | 1/20 | 0.42 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 5/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.40 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.40 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.40 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19003736 | 1.00 | LMNA (0.52) | LMNAL3MBTL1CA2KMT2AALDH1A1 | |
| SCHEMBL3443847 | 1.00 | LMNA (0.52) | LMNAL3MBTL1CA2KMT2AALDH1A1 | |
| SCHEMBL20824955 | 0.87 | ALDH1A1 (0.52) | LMNAL3MBTL1CA2KMT2AALDH1A1 | |
| SCHEMBL5235095 | 0.81 | KMT2A (0.64) | LMNAL3MBTL1CA2KMT2AALDH1A1 | |
| SCHEMBL6289914 | 0.81 | KMT2A (0.64) | LMNAL3MBTL1CA2KMT2AALDH1A1 | |
| SCHEMBL7911619 | 0.81 | KMT2A (0.64) | LMNAL3MBTL1CA2KMT2AALDH1A1 | |
| SCHEMBL845363 | 0.79 | CA2 (0.61) | LMNAL3MBTL1CA2KMT2AALDH1A1 | |
| SCHEMBL845362 | 0.79 | CA2 (0.61) | LMNAL3MBTL1CA2KMT2AALDH1A1 | |
| SCHEMBL19958893 | 0.79 | LMNA (0.57) | LMNAL3MBTL1CA2KMT2AALDH1A1 | |
| SCHEMBL4256710 | 0.79 | CA2 (0.61) | LMNAL3MBTL1CA2KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2796491-A1 | Composition for devulcanization of sulfur-cured rubber and method of devulcanization using this composition | Vorobyev, Leonid (US) | 2014-10-29 | — | — | EP | claimed |
| JP-63264411-A | — | — | None | — | — | JP | disclosed |
| US-11672811-B2 | Materials and methods for suppressing and/or treating bone related diseases and symptoms | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2023-06-13 | — | — | US | disclosed |
| US-11289238-B2 | Compositions for the filling of high aspect ratio vertical interconnect access (VIA) holes | HERAEUS PRECIOUS METALS NORTH AMERICA CONSHOHOCKEN LLC (US) | 2022-03-29 | — | — | US | disclosed |
| US-20210174983-A1 | COMPOSITIONS FOR THE FILLING OF HIGH ASPECT RATIO VERTICAL INTERCONNECT ACCESS (VIA) HOLES | HERAEUS PRECIOUS METALS NORTH AMERICA CONSHOHOCKEN LLC | 2021-06-10 | — | — | US | disclosed |
| US-10030016-B2 | Heterocyclic compounds useful as PDK1 inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-9856265-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN SCIENCES IRELAND UC (IE) | 2018-01-02 | — | — | US | disclosed |
| US-20170226111-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-08-10 | — | — | US | disclosed |
| US-9623022-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN SCIENCES IRELAND UC (IE) | 2017-04-18 | — | — | US | disclosed |
| US-9546165-B2 | Heterocyclic compounds useful as PDK1 inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| EP-0714885-B1 | Preparation process of aminoacetamide derivative | EISAI CO LTD (JP) | 1999-09-01 | — | — | EP | disclosed |
| EP-0473206-B1 | Compositions containing a terminal-modified block copolymer | ASAHI CHEMICAL IND (JP) | 1999-06-23 | — | — | EP | disclosed |
| EP-0714885-A2 | Preparation process of aminoacetamide derivative | EISAI CHEMICAL CO., LTD. (JP) | 1996-06-05 | — | — | EP | disclosed |
| EP-0473206-A2 | Compositions containing a terminal-modified block copolymer | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1992-03-04 | — | — | EP | disclosed |
| JP-S63264411-A | CARCINOSTATIC AGENT | RIKAGAKU KENKYUSHO | 1988-11-01 | — | — | JP | disclosed |
| EP-0231030-A2 | A thermochromic polyurethane foam and a method for producing the foam | MATSUI SHIKISO CHEMICAL CO., LTD (JP) | 1987-08-05 | — | — | EP | disclosed |
| EP-0148094-A2 | Anti-tumor agent comprising an O-benzylidene-L-ascorbic acid or a salt thereof, and the production of the latter compound | Kochi, Mutsuyuki (JP) | 1985-07-10 | — | — | EP | disclosed |
| US-4357476-A | Nonylamines | CIBA GEIGY CORPORATION, N.Y. (US) | 1982-11-02 | — | — | US | disclosed |
| US-4139560-A | Nonylamines | CIBA GEIGY CORPORATION (US) | 1979-02-13 | — | — | US | disclosed |
| US-4073767-A | Hydrogen phosphonates and polymers containing them as flame retardants | MONSANTO COMPANY (US) | 1978-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226111-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | CYP2A7, CYP3A7, HCCS | LMNA 3526/4885L3MBTL1 1862/4885CA2 4402/4885 |
| US-11672811-B2 | Materials and methods for suppressing and/or treating bone related diseases and symptoms | SOST, TSG101, BST2 | LMNA 790/4885L3MBTL1 460/4885CA2 1317/4885 |
| US-10030016-B2 | Heterocyclic compounds useful as PDK1 inhibitors | PDK1, PDK2, PDK3 | LMNA 3553/4885L3MBTL1 1895/4885CA2 3331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.